← All trials
NCT04113226
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2019
- Primary completion
- Mar 31, 2022
- Completion date
- Mar 31, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 114
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of Picardie Jules VerneLead sponsor
- Centre Henri BecquerelCollaborator
- CHU Henri MondorCollaborator
- University of ParisCollaborator
- Institut BergoniéCollaborator
- Institut BergoniéOverall official - principal investigator
- University of ParisOverall official - principal investigator
- CHU Henri MondorOverall official - principal investigator
- University of Nice Sophia AntipolisOverall official - principal investigator
- Assistance Publique - Hôpitaux de ParisOverall official - principal investigator
- Assistance Publique - Hôpitaux de ParisCollaborator
- Hospital AvicenneOverall official - principal investigator
- Groupe Hospitalier Public Sud OiseCollaborator
- University of Nice Sophia AntipolisCollaborator
- Territorial Hospital Group (GHT) Rance EmeraudeOverall official - principal investigator
- Hospital Center of PérigueuxOverall official - principal investigator
- University of Caen-NormandieOverall official - principal investigator
- Hospital Center Saint-QuentinOverall official - principal investigator
- Centre Hospitalier COMPIEGNEOverall official - principal investigator
- Centre Hospitalier ABBEVILLEOverall official - principal investigator
- Centre Henri BecquerelOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.